Enclomiphene for testosterone: the evidence, and what telehealth ads don't say
Enclomiphene raises testosterone by stimulating your own production — and unlike testosterone replacement, it preserves sperm counts. The part the ads skip: it is not FDA-approved (the Androxal application was not approved in 2015), so every enclomiphene prescription today is off-label compounded medication.
2 min readUpdated
- Not approved
- FDA status — no approved enclomiphene product exists
- Compounded
- every US prescription is compounded, off-label
- Fertility
- its edge over TRT: preserves sperm production
- SERM
- drug class — stimulates your own testosterone
Jump to section
How enclomiphene differs from testosterone therapy
Enclomiphene is the trans-isomer of clomiphene, a selective estrogen receptor modulator (SERM). Instead of adding external testosterone, it blocks estrogen feedback at the pituitary, which raises LH and FSH — your body's own signals to produce testosterone. Clinical studies found it raises testosterone into the normal range while maintaining sperm counts, whereas exogenous testosterone suppresses them.
That fertility preservation is the entire reason enclomiphene exists as a category: it's aimed at men with low testosterone who want to keep the option of having children.
The regulatory reality the marketing skips
There is no FDA-approved enclomiphene product. The manufacturer's application (Androxal) did not win approval in 2015, and development lapsed. What telehealth clinics prescribe today is compounded enclomiphene — legal when individually prescribed, but without the manufacturing standardization, bioequivalence testing, or long-term safety data an approved drug carries.
Off-label compounded status doesn't mean it doesn't work — the published trials are real — but it does mean quality varies by compounding pharmacy, insurers won't cover it, and the long-term safety file is thinner than for approved therapies. Ask any prescriber which pharmacy compounds it and what testing they do.
Who it plausibly fits, and who it doesn't
Reasonable candidates: younger men with secondary hypogonadism (a signaling problem, not a testicular one) who want to preserve fertility. Poor candidates: men with primary hypogonadism — if the testes can't respond to LH, raising LH achieves little — and anyone who hasn't had morning testosterone measured twice plus LH/FSH to establish the diagnosis.
The honest comparison: FDA-approved clomiphene (mixed isomers) is often used off-label for the same purpose and is cheap as a generic; enclomiphene's theoretical advantage is dropping the zuclomiphene isomer linked to more estrogenic side effects. Head-to-head long-term data between the two is limited.
Sources
Primary sources cited above. FDA labeling, peer-reviewed trials, and specialty-society guidelines only.
- Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone · BJU International, 2016
- Drugs@FDA database (no approved enclomiphene product) · U.S. Food and Drug Administration
People also ask
Is enclomiphene FDA-approved?
No. The enclomiphene application (Androxal) was not approved by the FDA in 2015, and no approved product exists. All US enclomiphene prescriptions today are compounded medication prescribed off-label — legal, but without the standardization and long-term safety data of an approved drug.
Does enclomiphene work as well as TRT?
It raises testosterone by a different route — stimulating your own production rather than replacing it. Studies show it brings testosterone into the normal range while preserving sperm counts, which TRT suppresses. For symptom relief, response varies; men with primary hypogonadism (testicular failure) typically need TRT instead.
Why do telehealth clinics prescribe enclomiphene instead of clomiphene?
Enclomiphene is clomiphene with the zuclomiphene isomer removed — the isomer associated with more estrogenic side effects, so the theory is fewer side effects. Generic clomiphene is far cheaper and also used off-label for the same purpose; head-to-head long-term comparisons are limited. Cost and compounding margins also play a role in what gets marketed.